SubsidieMeestersMacrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.
Projectdetails
Introduction
Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer. About 300,000 women are diagnosed with ovarian cancer each year, and the number of deaths is estimated at 180,000 worldwide each year. Ovarian cancer metastasizes early in its development, often before it's diagnosed.
Treatment Overview
Ovarian cancer treatment involves surgery with frontline platinum-based chemotherapy. As many as 15-30% of patients with ovarian cancer have primary platinum-resistant or refractory disease. The recurrence of ovarian cancer is now considered a sign of an incurable disease, as it becomes platinum-resistant.
Project Description
The project MACOV aims to develop an innovative allogeneic, “ready-to-use” macrophage-based therapy for platinum-resistant ovarian cancer. This is a groundbreaking, first-in-class therapy that shows very high efficacy in multiple solid tumors of unmet medical need.
Mechanism of Action
These cells are equipped with targeted therapy drugs complexed with the carrier protein, ensuring their stability in the carrier cell. The protein-drug complex is transferred specifically to cancer cells. The whole concept of this cell therapy is based on the groundbreaking scientific discoveries of MDC (Macrophage-Drug Conjugate).
Research Grants and Recognition
Two European Research Council (ERC) grants were received to study the molecular basis of the discovered mechanism in 2016 and 2020. In 2018, this project was selected to be promoted as one of the 10 European projects during the ERC 10th Anniversary.
Project Goals
The MACOV project will generate a complete efficacy data package for the pre-clinical development of the MDC-735 product, consisting of:
- Efficacy in multiple animal models for platinum-resistant ovarian cancer
- Pharmacokinetics (PK) and pharmacodynamics (PD) studies
- Toxicology studies
- Consolidation of intellectual property (IP)
- Validation of the business case
Expected Outcomes
The result of the project will be a validated cell therapy product for platinum-refractory ovarian cancer, tested for effectiveness and ready-to-use for the Phase I clinical trial.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.998 |
| Totale projectbegroting | € 2.499.998 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CELLIS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Achieving the golden Grail in solid tumor treatmentThe McHAP project aims to commercialize Macrophage-Drug Conjugates for solid tumor treatment by confirming tumor-resistance mechanisms and optimizing immune responses for clinical application. | ERC Proof of... | € 150.000 | 2023 | Details |
Allogeneic Macrophages for Cancer TherapyONCOMAC aims to prepare a preclinical proof-of-concept study for genetically engineered human macrophages as a novel cancer cell therapy, ensuring compliance with regulatory standards for clinical trials. | ERC Proof of... | € 150.000 | 2022 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Ruthenium-containing Polymers against Ovarian CancersThis project aims to enhance survival rates in advanced ovarian cancer by validating a novel ruthenium-based drug delivery system in patient-derived xenograft models to overcome platinum resistance. | ERC Proof of... | € 150.000 | 2023 | Details |
Curing ovarian cancer through autoantibody-based therapyThis project aims to develop a novel MUC16-specific antibody drug conjugate (2B5-ADC) for ovarian cancer therapy, enhancing efficacy and targeting while preparing for phase 1 clinical trials. | ERC Proof of... | € 150.000 | 2024 | Details |
Achieving the golden Grail in solid tumor treatment
The McHAP project aims to commercialize Macrophage-Drug Conjugates for solid tumor treatment by confirming tumor-resistance mechanisms and optimizing immune responses for clinical application.
Allogeneic Macrophages for Cancer Therapy
ONCOMAC aims to prepare a preclinical proof-of-concept study for genetically engineered human macrophages as a novel cancer cell therapy, ensuring compliance with regulatory standards for clinical trials.
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
Ruthenium-containing Polymers against Ovarian Cancers
This project aims to enhance survival rates in advanced ovarian cancer by validating a novel ruthenium-based drug delivery system in patient-derived xenograft models to overcome platinum resistance.
Curing ovarian cancer through autoantibody-based therapy
This project aims to develop a novel MUC16-specific antibody drug conjugate (2B5-ADC) for ovarian cancer therapy, enhancing efficacy and targeting while preparing for phase 1 clinical trials.